Skip to main content
. 2019 Jan 18;10(6):673–683. doi: 10.18632/oncotarget.26586

Figure 4. MDM2 modulates sensitivity to paclitaxel in ovarian cancer cell lines.

Figure 4

(A) Western blot. Cells were transfected with MDM2-siRNA or control-siRNA. Twenty-four hours after incubation, cell lysates were collected, and MDM2 expression was evaluated. (B) MTS assay. Cells were transfected with MDM2-siRNA or control-siRNA. Twenty-four hours after incubation, cells were treated with paclitaxel for 72 hours and cell viability was assessed. (C) Western blot. Cells were transfected with an MDM2 expression plasmid (MDM2(+)) or empty vector. Forty-eight hours after transfection, cell lysates were collected. (D) MTS assay. Forty-eight hours after transfection with an MDM2 expression plasmid (MDM2(+)) or empty vector, cells were treated with paclitaxel for 72 hours and viability was assessed. Blots are representative of three experiments. MTS assays were performed in triplicate. Data are represented as mean ± SE and are obtained from three independent experiments. *P < 0.05, **P < 0.01.